Key Drivers
- Margin Strength
- Zero Leverage
- Solid Cash Flow
AIAI Summary
UTHR is no longer just a high-margin PAH cash machine but a broader self-funding transplant/regenerative platform, yet with revenue growth softening and the stock still at a premium, the key takeaway is that upside now depends on LungFX, Thymmune, and core pipeline programs translating clinical momentum into real commercial acceleration.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Zero Leverage
- •Solid Cash Flow
UTHR remains a high-quality, cash-generative biotech with exceptional margins, zero leverage and strong liquidity, but its premium valuation and softer Q1 2026 margins make the stock less compelling at current levels.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows trend
- •Range-top close
- •Follow-through needed
UTHR ended last month at the top of its range with higher lows and improving momentum, but it still needs a clean breakout above the recent high to confirm the move and hold the mid-$540s support.
Steady rebound from the 2026-06-18 low back above the late-June range
Sentiment & News
Key News Insights:
- •LungFX approval
- •Thymmune acquisition
- •Pipeline expansion
UTHR strengthened its transplant and regenerative medicine strategy with FDA approval for LungFX and the acquisition of Thymmune Therapeutics, expanding its organ-support and cell-therapy pipeline.
This is a modestly positive development for UTHR, reinforcing its long-term growth story through both regulatory progress and strategic pipeline building
Similar Companies in Healthcare
Other companies in the same sector with AI ratings